✦ LIBER ✦

[503] OVERLAPPING OF LAMIVUDINE AND ADEFOVIR BEFORE SWITCHING TO ADEFOVIR MONOTHERAPY IN LAMIVUDINE RESISTANT CHRONIC HEPATITIS B: IS IT NECESSARY?

✍ Scribed by H.I. Lee; J.H. Lee; W.Y. Tak; J.S. Hwang; S.H. Bae; T.H. Lee; C.K. Lee; S.K. Baik; M.Y. Kim; N.H. Park; S.H. Ryu; G.Y. Gwak; K.C. Koh; S.W. Paik; B.C. Yoo

Book ID: 118567118
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 289 KB
Volume: 46
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(07)62101-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[502] ADEFOVIR AND LAMIVUDINE COMBINATIO

[502] ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IS SUPERIOR TO ADEFOVIR MONOTHERAPY FOR LAMIVUDINE-RESISTANT PATIENTS WITH HBeAg-NEGATIVE CHRONIC HEPATITIS B

✍ P. Lampertico; A. Marzano; M. Levrero; T. Santantonio; V. Di Marco; M. Brunette; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Adefovir and lamivudine combination ther

Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B

✍ P. Lampertico; A. Marzano; M. Levrero; T. Santantonio; V. Di Marco; M. Brunetto; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Efficacy of adefovir add-on lamivudine r

Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B

✍ Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract No study has reported on the comparative effect of adefovir (ADV) add‐on lamivudine (LAM) versus switching to entecavir (ETV) in LAM‐resistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAM‐resistant patients were enrolled (47 LAM + ADV and 45

Combination of Lamivudine and adefovir t

Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy

✍ L.-C. Wang; E.-Q. Chen; J. Cao; L. Liu; J.-R. Wang; B.-J. Lei; H. Tang 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Adding-on versus switching-to adefovir t

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B

✍ Irene Rapti; Evangelini Dimou; Panayota Mitsoula; Stephanos J. Hadziyannis 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views

We studied the long-term efficacy of adefovir dipivoxil (ADV) treatment in 42 HBeAgnegative patients with chronic hepatitis B (CHB) who had developed genotypical lamivudine (LAM) resistance with virological and clinical breakthroughs under long-term LAM treatment. Patients were allocated in 2 treatm

Increased risk of adefovir resistance in

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy

✍ Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu L 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood. We compared the emergence of the ADV-resistant mutations rt